GHK-Cu Capsules

Oral capsule format containing GHK-Cu. Route-specific stability and bioavailability require direct evidence.

The biology of orally delivered material may differ substantially from topical, injectable, or in-vitro systems.

Current literature places GHK-Cu Capsules at Evidence Level III, limited or preliminary human evidence.

Evidence Level III

Capsule presentation creates strong human-use implications and requires counsel review.

Safety and toxicology data are limited; consult the primary literature for model-specific findings.

Investigational research material; not an approved drug product.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.